Clinical trials: Diabetes in Adolescence
- Condition Diabetes in Adolescence
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Type 2 Diabetes
A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes.
- Trial name
- AWARD-PEDS (NCT02963766)
- Testing
- Dulaglutide
- Where
- 61 sites in United States, Brazil and 9 more
- Volunteers
- 154 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus, Type2 Diabetes Mellitus
Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics
The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT03966911
- Testing
- Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter
- Where
- 15 sites in United States
- Volunteers
- 335 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 2
A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effect of canagliflozin relative to placebo on glycated hemoglobin (HbA1c) after 26 weeks of treatment, and to assess the overall safety and tolerability of canagliflozin.
- Trial name
- NCT03170518
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg
- Where
- 106 sites in United States, Brazil and 8 more
- Volunteers
- 171 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus
Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM
The purpose of this study is to evaluate the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects with Type 2 diabetes mellitus (T2DM) following oral administration of Saxagliptin and…
- Trial name
- NCT01525225
- Testing
- Metformin immediate release (IR), Saxagliptin, Metformin IR
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals in…
- Trial name
- NCT01835431
- Testing
- insulin degludec/insulin aspart, insulin aspart, insulin detemir
- Where
- 73 sites in United States, Belgium and 13 more
- Volunteers
- 362 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
The purpose of this study was to assess how glucagon administered nasally, using a nasal dosing delivery device, works in children and adolescents compared with commercially-available glucagon given by injection.
- Trial name
- NCT01997411
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Children and Adolescent With Type 2 Diabetes
Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
The study examines the Safety and efficacy study of exenatide once weekly in children and adolescents with type 2 diabetes
- Trial name
- NCT01554618
- Testing
- Exenatide Once Weekly
- Where
- 35 sites in United States, Bulgaria and 5 more
- Volunteers
- 84 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin
This trial is conducted globally. The aim of the trial is to investigate the efficacy and safety of insulin detemir versus insulin Neutral Protamine Hagedorn (NPH) in combination with the maximum tolerated dose of metformin and…
- Trial name
- iDEAt2 (NCT02131272)
- Testing
- Insulin detemir, Insulin NPH, Diet/exercise
- Where
- 82 sites in United States, Argentina and 22 more
- Volunteers
- 42 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
The primary objective of this study is to test the hypothesis that glycemic control, as measured by change in hemoglobin A1c (HbA1c) from baseline to endpoint, with exenatide is superior to that of placebo after 28 weeks of…
- Trial name
- NCT00658021
- Testing
- Exenatide
- Where
- 53 sites in United States, Brazil and 6 more
- Volunteers
- 122 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
This study compares 2 medicines for type 2 diabetes: semaglutide (new medicine) and a dummy medicine (placebo). Semaglutide will be tested to see how well it works compared to the dummy medicine.
- Trial name
- PIONEER TEENS (NCT04596631)
- Testing
- Oral semaglutide
- Where
- 97 sites in United States, Australia and 20 more
- Volunteers
- 132 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes
The main objective of this study is to identify the dose of linagliptin in paediatric patients. Other efficacy objectives include the comparison of the lowering effect of linagliptin low dose, high dose and placebo on the fasting…
- Trial name
- NCT01342484
- Testing
- BI1356 low dose, BI1356 high dose
- Where
- 25 sites in United States, Canada and 7 more
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes
Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes
The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control when compared to subjects using the Paradigm…
- Trial name
- STAR1 (NCT00211510)
- Testing
- Paradigm 722 sensor augmented pump, Paradigm 715 insulin pump
- Where
- 7 sites in United States
- Volunteers
- 146 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
MiniMed™ 670G System China Study for Type I Diabetic
The purpose of this study is to obtain clinical data in Chinese patients to support product registration of the MiniMed™ 670G system with the National Medical Product Administration (NMPA) in China.
- Trial name
- NCT04663295
- Testing
- MiniMed™ 670G system
- Where
- 4 sites in China
- Volunteers
- 74 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus
Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)
This clinical trial will explore the safety and effect of autologous ex vivo expanded polyclonal regulatory T-cells on beta cell function in patients, aged 8 to 17, with recent onset T1DM.
- Trial name
- NCT02691247
- Testing
- CLBS03 Low Dose, CLBS03 High Dose
- Where
- 15 sites in United States
- Volunteers
- 113 people
- Sponsor
- Lisata Therapeutics, Inc.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to assess the efficacy and safety of liraglutide in the paediatric population in order to potentially address the unmet need for treatment of children and adolescents…
- Trial name
- Ellipse™ (NCT01541215)
- Testing
- liraglutide, metformin
- Where
- 185 sites in United States, Australia and 34 more
- Volunteers
- 135 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents
To assess the safety and efficacy of Exubera on pulmonary function and glycemic control in subjects ages 6-17 over a 1 year period.
- Trial name
- NCT00479258
- Testing
- Inhaled insulin (Exubera), Subcutaneous Insulin (subject's prescribed)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
PK Study of Dapagliflozin in Pediatric Subjects With T2DM
The primary purpose of this study is to evaluate the pharmacokinetics (PK) of Dapagliflozin in pediatric subjects with type 2 diabetes mellitus (T2DM)
- Trial name
- NCT01525238
- Testing
- Dapagliflozin
- Where
- 17 sites in United States, Mexico
- Volunteers
- 53 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus
A Study of LY900014 in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 1 diabetes mellitus. There are 2 parts to this study.
- Trial name
- NCT03465878
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Canada, Germany
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Type2 Diabetes, Diabetes Mellitus
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both.
- Conditions
- Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D
- Trial name
- SURPASS-PEDS (NCT05260021)
- Testing
- Tirzepatide Dose 1, Tirzepatide Dose 2
- Where
- 51 sites in United States, Australia and 7 more
- Volunteers
- 99 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
The aim of the study is to generate pharmacokinetic and pharmacodynamic data to identify the safe-effective dose of empagliflozin in children and adolescents aged 10 to less than 18 years with type 2 diabetes mellitus.
- Trial name
- NCT02121483
- Testing
- empagliflozin medium dose, empagliflozin high dose, empagliflozin low dose
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 27 people
- Sponsor
- Boehringer Ingelheim